The cell therapy technologies market, worth USD 4.2 billion in 2023, is anticipated to grow to USD 7.8 billion by 2028 at a CAGR of 13.3%. Increasing investments and the rise of personalized medicine are key drivers. Major companies like Thermo Fisher Scientific and Sartorius AG dominate the market, creating high entry barriers for smaller companies. The market segments include product types, processes, and cell types, with biopharma companies at the forefront. North America holds the largest share, propelled by industry leaders and research-driven support. Strategic collaborations are boosting innovation.
Cell Therapy Technologies Market Dynamics
DRIVER: Rising incidence of chronic and infectious diseases
Cell therapy plays a crucial role in providing diagnostic and prognostic information for various diseases, including HIV/AIDS, cancer, and infectious diseases. Through innovative cellular-based approaches, it enables researchers and healthcare professionals to gain insights into disease mechanisms, disease progression, and treatment responses. The global population growth, climate change, and increased interaction between humans and animals have created an environment where the emergence of new virus outbreaks is more likely. Cell therapy research and applications are vital in addressing these challenges by providing advanced diagnostic tools, therapeutic interventions, and a deeper understanding of disease mechanisms.
RESTRAINT: High cost of cell-based research and low success rate
Cell biology research focuses on developing new therapies like stem cell and gene therapies. To obtain accurate results, high-quality instruments, reagents, and related products are essential. However, meeting regulatory guidelines and maintaining stringent quality standards in cell biology research incurs high costs. This poses a challenge for institutes and small-scale companies with limited budgets, as they may struggle to afford expensive research products.
OPPORTUNITY: Increased focus on personalized medicine
Precision medicine is an evolving approach to disease treatment and prevention that considers individual differences in genes, environment, and lifestyle. It involves tailoring drug selection to each patient based on their specific condition and medical history. While its application expands to various diseases, oncology has made notable progress in precision medicine. This personalized approach to diagnosis, treatment, and prevention utilizes comprehensive patient information, including genetics, environment, and lifestyle, to make more accurate decisions.
CHALLENGE: Survival of small players and new entrants
Small players and new entrants in the market face a significant challenge in terms of survival. Such as Thermo Fisher Scientific (US), Merck KGaA (Germany), Lonza (Switzerland), Sartorius AG (Germany), and Danaher (US) account for a major share of the market. This makes it challenging for smaller players and new entrants to compete effectively. Additionally, the market demands substantial investments in research and development (R&D) and the launch of innovative products, creating difficulties for smaller players to sustain their operations and compete with established players that have substantial R&D budgets.
The process segment dominated the cell therapy technologies industry in 2022.
Based on process, the global cell therapy technologies market is segmented into cell processing cell preservation, distribution and handling, process monitoring and quality control. Cell processing segment dominated process segment in 2022. Availability and launch of technologically advanced cell processing equipment is likely to contribute to the growth of the segment.
The biopharmaceutical & biotechnology companies segment accounted for the segment dominated cell therapy technologies industry in 2022.
Based on end users, the cell therapy technologies market is segmented into biopharmaceutical & biotechnology companies, CRO’s & CMOs, research institutes and cell banks. In 2022, biopharmaceutical and biotechnology companies held dominant share owing to various factors such as increased investment in development of cell based therapies. Rising research institutes and biopharma companies collaborations is further anticipated to drive the growth of the segment at faster pace.
North America held a dominant share in the regional market for the cell therapy technologies industry in 2022.
Geographically, the cell therapy technologies markets are segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2022, North America accounted for the largest share of the market, followed by Europe & Asia Pacific. The region's dominant position can be attributed to several key factors such as presence of leading market players and increased government investments in cell-based research.
Key players in the cell therapy technologies market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Becton, Dickinson, and Company (US), Lonza Group (Switzerland), Sartorius AG (Germany) and among others.
Recent Developments of Cell Therapy Technologies Industry:
- In March 2023, Thermo fisher scientific Inc. entered into collaboration with Arsenal biosciences Inc. The collaboration allows development of manufacturing process for new cancer treatments. This research and process development-focused collaboration has enabled ArsenalBio to develop a robust manufacturing process for their next-generation, programmable autologous T cells for the treatment of cancer.
- In March 2023, Danaher entered into partnership with the University of pennsylvania's center for cellular immunotherapies to solve manufacturing difficulties that are affecting the adoption of cell therapies.
- In March 2023, Lonza and Vertex have entered a strategic collaboration to facilitate the manufacturing of Vertex's portfolio of investigational stem cell-derived islet cell therapies. As part of the collaboration, Vertex and Lonza will establish a dedicated manufacturing facility specifically for T1D cell therapies.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets Inc.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
UK +44-800-368-9399
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com/
